GlassScriptPhysician profile
Madeline Vaitas
NPI 1700611860
$681.66
in general payments reported to CMS, 2019-2025
17 companies · $682 in 2025
The $682 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $131.92 | 2025 | Evenity, Otezla, Repatha |
| Madrigal Pharmaceuticals | $63.33 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $54.56 | 2025 | Capvaxive, Lagevrio, Verquvo |
| Abbvie INC. | $52.84 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.35 | 2025 | |
| Novo Nordisk INC | $51.16 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $33.31 | 2025 | Camzyos |
| Janssen Biotech, INC. | $33.26 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $30.67 | 2025 | Breztri |
| Edwards Lifesciences Corporation | $29.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.63 | 2025 | Jardiance |
| Eisai INC. | $28.07 | 2025 | |
| Exact Sciences Corporation | $24.83 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $21.99 | 2025 | |
| Esperion Therapeutics, INC. | $16.30 | 2025 | Nexletol |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.14 | 2025 | Arexvy, Shingrix |
| Alnylam Pharmaceuticals INC. | $14.30 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Vaitas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.